Travere Therapeutics (TVTX) Enterprise Value (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Enterprise Value came in at -$78.4 million in Q1 2026, down 26.6% YoY from -$106.8 million in Q1 2025, and up 15.77% on a QoQ basis from -$93.0 million in Q4 2025.
Travere Therapeutics (TVTX) Enterprise Value (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 14 years of Enterprise Value data on file, last reported at -$78.4 million in Q1 2026.
- Quarterly Enterprise Value fell 26.6% year-over-year to -$78.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.4 million (down 26.6% YoY) and the FY2025 annual result came in at -$93.0 million, down 58.94% from the prior year.
- Enterprise Value climbed to -$78.4 million in Q1 2026, from -$93.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$32.3 million in Q2 2024 to a low of -$256.6 million in Q1 2022.
- A 5-year average of -$98.5 million and a median of -$75.2 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 74.76% — and 2025, when it tumbled 204.68%.
- Tracing TVTX's Enterprise Value over 5 years: stood at -$61.7 million in 2022, then grew by 5.69% to -$58.2 million in 2023, then dropped by 0.62% to -$58.5 million in 2024, then slumped by 58.94% to -$93.0 million in 2025, then increased by 15.77% to -$78.4 million in 2026.
- The last three Enterprise Value figures came in at -$78.4 million (Q1 2026), -$93.0 million (Q4 2025), and -$110.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -117.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.74 Mn |
| Mar 31, 2026 | -78.36 Mn |
| Dec 31, 2025 | -93.04 Mn |
| Sep 30, 2025 | -110.93 Mn |
| Jun 30, 2025 | -75.15 Mn |
| Mar 31, 2025 | -61.90 Mn |
| Dec 31, 2024 | -58.54 Mn |
| Sep 30, 2024 | -36.41 Mn |
| Jun 30, 2024 | -32.29 Mn |
| Mar 31, 2024 | -43.25 Mn |
| Dec 31, 2023 | -58.18 Mn |
| Sep 30, 2023 | -144.24 Mn |
| Jun 30, 2023 | -70.87 Mn |
| Mar 31, 2023 | -161.38 Mn |
| Dec 31, 2022 | -61.69 Mn |
| Sep 30, 2022 | -151.34 Mn |
| Jun 30, 2022 | -179.76 Mn |
| Mar 31, 2022 | -256.57 Mn |
| Dec 31, 2021 | -165.75 Mn |
| Sep 30, 2021 | -150.33 Mn |